Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS Med
Main Authors: Lawlor, Brian, Segurado, Ricardo, Kennelly, Sean, Olde Rikkert, Marcel G. M., Howard, Robert, Pasquier, Florence, Börjesson-Hanson, Anne, Tsolaki, Magda, Lucca, Ugo, Molloy, D. William, Coen, Robert, Riepe, Matthias W., Kálmán, János, Kenny, Rose Anne, Cregg, Fiona, O'Dwyer, Sarah, Walsh, Cathal, Adams, Jessica, Banzi, Rita, Breuilh, Laetitia, Daly, Leslie, Hendrix, Suzanne, Aisen, Paul, Gaynor, Siobhan, Sheikhi, Ali, Taekema, Diana G., Verhey, Frans R., Nemni, Raffaello, Nobili, Flavio, Franceschi, Massimo, Frisoni, Giovanni, Zanetti, Orazio, Konsta, Anastasia, Anastasios, Orologas, Nenopoulou, Styliani, Tsolaki-Tagaraki, Fani, Pakaski, Magdolna, Dereeper, Olivier, de la Sayette, Vincent, Sénéchal, Olivier, Lavenu, Isabelle, Devendeville, Agnès, Calais, Gauthier, Crawford, Fiona, Mullan, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6152871/
https://ncbi.nlm.nih.gov/pubmed/30248105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002660
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados